Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Hills RK., Gale R., Linch DC., Huntly BJP., Papaemmanuil E., Vyas P., Burnett AK., Russell NH.

DOI

10.1182/blood-2018-99-116482

Type

Conference paper

Publication Date

2018-01-01T00:00:00+00:00

Volume

132

Permalink More information Close